MagForce AG announces results of 2021 Annual General Meeting and changes to the Supervisory Board
DGAP-News: MagForce AG
/ Key word(s): AGM/EGM
MagForce AG announces results of 2021 Annual General Meeting and changes to the Supervisory Board Berlin, Germany, and Nevada, USA, August 12, 2021 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced the results of the 2021 Annual General Meeting (AGM). Due to the COVID-19 pandemic, the meeting was held virtually, as in the previous year. In total, 44.5 percent of the share capital with voting rights was represented. The Annual General Meeting approved resolution items 2 to 5 as well as 7, 8 and 10 - most of them with a significant majority. Resolution item 6 (Authorized Capital 2021) did not receive the required qualified majority. Norbert Neef, Chairman of the Supervisory Board, informed the Annual General Meeting that he resigns from office effective as of the end of the AGM. Thus, the vote on agenda item 9 was not applicable. Following the suggestion of the supplementary motion of shareholder Avalon Capital One GmbH dated July 29, 2021, Stefan Schütze, attorney and Managing Director of C3 Management GmbH, was elected to the Supervisory Board from the end of this AGM until the end of the AGM that resolves on the ratification of the actions of the members of the Supervisory Board for fiscal year 2021. The Supervisory Board of MagForce AG, which also includes Klemens Hallmann and Aaron Weaver, will hold a constituent meeting shortly to vote on the new chair. Additional information on the 2021 Annual General Meeting 2021, including detailed voting results, the video address by CEO Ben J. Lipps, as well as the Management presentation on current operational developments, the overview of fiscal year 2020 and outlook for the current year, are available on the Company's website at https://www.magforce.com/en/home/for-press-investors/#general_meetings. About MagForce AG and MagForce USA, Inc. NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.
Contact: This release may contain forward-looking statements and information which may be identified by terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.
12.08.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | MagForce AG |
Max-Planck-Straße 3 | |
12489 Berlin | |
Germany | |
Phone: | +49 (0)30 308 380 0 |
Fax: | +49 (0)30 308 380 99 |
E-mail: | info@magforce.com |
Internet: | www.magforce.com |
ISIN: | DE000A0HGQF5 |
WKN: | A0HGQF |
Indices: | Scale 30 |
Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Stuttgart, Tradegate Exchange |
EQS News ID: | 1226201 |
End of News | DGAP News Service |
Editor Details
-
Company:
- EQS Newsfeed
- Website: